Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy

被引:24
作者
Mazzarotto, Francesco [1 ,2 ,3 ,4 ]
Olivotto, Iacopo [1 ,2 ]
Walsh, Roddy [5 ]
机构
[1] Careggi Univ Hosp, Cardiomyopathy Unit, Florence, Italy
[2] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[3] Royal Brampton & Harefield NHS Fdn Trust, Cardiovasc Res Ctr, London, England
[4] Imperial Coll London, Natl Heart & Lung Inst, London, England
[5] Acad Med Ctr, Heart Ctr, Dept Clin & Expt Cardiol, Amsterdam, Netherlands
关键词
Cardiomyopathy; Whole-exome sequencing; Whole-genome sequencing; Clinical genetic testing; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; SUDDEN CARDIAC DEATH; MEDICAL GENETICS; AMERICAN-COLLEGE; HUMAN HEART; HIGH-RISK; MUTATIONS; DISEASE; MYOSIN; VARIANTS;
D O I
10.1007/s10557-020-06948-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As the price of next-generation sequencing keeps decreasing, cost is becoming a less important discriminator for diagnostic laboratories in choosing the preferred type of approach to genetic testing. Genome-wide sequencing strategies will plausibly become the standard first-tier tools for genetic testing, with the potential for deeper understanding of the genetic architecture of cardiomyopathies and discovery of the underlying aetiology in the many patients in whom the genetic cause remains elusive. Routine usage of extended sequencing assays will also enable "genetic-first diagnostics", particularly for those patients affected with syndromic conditions of unclear genetic origin, often resulting in costly and distressing diagnostic odysseys before reaching a diagnosis. However, access to genome-wide data for all patients will need to be managed with rigour and caution by (cardiovascular) genetic professionals to avoid erroneous variant pathogenicity assertions and over-reporting uncertain findings, both damaging scenarios to patients and their family members. Researchers will also be required to adopt robust methods to demonstrate novel genetic associations with disease, given the high "narrative potential" of such large datasets and the dangers of generating further false positive associations (that have previously blighted the field of cardiac genetics). Here, we discuss advantages and dangers associated with the routine adoption of whole-exome (and whole-genome) sequencing in diagnostic facilities and in the research setting in the context of cardiomyopathies but relevant to several other conditions.
引用
收藏
页码:241 / 253
页数:13
相关论文
共 50 条
  • [21] Whole-exome sequencing establishes a diagnosis of Alstrom syndrome: a case report
    Liu, Ziqin
    Chen, Xiaobo
    TRANSLATIONAL PEDIATRICS, 2022, 11 (04) : 589 - 594
  • [22] The Application of Whole-Exome Sequencing in Patients With FUO
    Guo, Wanru
    Feng, Xuewen
    Hu, Ming
    Shangguan, Yanwan
    Xia, Jiafeng
    Hu, Wenjuan
    Li, Xiaomeng
    Zhang, Zunjing
    Shi, Yunzhen
    Xu, Kaijin
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 11
  • [23] Whole-Exome Sequencing of an Exceptional Longevity Cohort
    Nygaard, Haakon B.
    Erson-Omay, E. Zeynep
    Wu, Xiujuan
    Kent, Brianne A.
    Bernales, Cecily Q.
    Evans, Daniel M.
    Farrer, Matthew J.
    Vilarino-Guell, Carles
    Strittmatter, Stephen M.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2019, 74 (09): : 1386 - 1390
  • [24] Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage
    Barbitoff, Yury A.
    Polev, Dmitrii E.
    Glotov, Andrey S.
    Serebryakova, Elena A.
    Shcherbakova, Irina V.
    Kiselev, Artem M.
    Kostareva, Anna A.
    Glotov, Oleg S.
    Predeus, Alexander V.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [25] Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels
    Ramarao-Milne, P.
    Kondrashova, O.
    Patch, A. -M.
    Nones, K.
    Koufariotis, L. T.
    Newell, F.
    Addala, V.
    Lakis, V.
    Holmes, O.
    Leonard, C.
    Wood, S.
    Xu, Q.
    Mukhopadhyay, P.
    Naeini, M. M.
    Steinfort, D.
    Williamson, J. P.
    Bint, M.
    Pahoff, C.
    Nguyen, P. T.
    Twaddell, S.
    Arnold, D.
    Grainge, C.
    Basirzadeh, F.
    Fielding, D.
    Dalley, A. J.
    Chittoory, H.
    Simpson, P. T.
    Aoude, L. G.
    Bonazzi, V. F.
    Patel, K.
    Barbour, A. P.
    Fennell, D. A.
    Robinson, B. W.
    Creaney, J.
    Hollway, G.
    Pearson, J. V.
    Waddell, N.
    ESMO OPEN, 2022, 7 (04)
  • [26] Whole-exome sequencing study of hypospadias
    Chen, Zhongzhong
    Lei, Yunping
    Finnell, Richard H.
    Ding, Yu
    Su, Zhixi
    Wang, Yaping
    Xie, Hua
    Chen, Fang
    ISCIENCE, 2023, 26 (05)
  • [27] Whole-genome sequencing
    Morris, Huw R.
    Houlden, Henry
    Polke, James
    PRACTICAL NEUROLOGY, 2021, 21 (04) : 322 - +
  • [28] Clinical efficiency of simultaneous CNV-seq and whole-exome sequencing for testing fetal structural anomalies
    Chen, Xinlin
    Jiang, Yulin
    Chen, Ruiguo
    Qi, Qingwei
    Zhang, Xiujuan
    Zhao, Sheng
    Liu, Chaoshi
    Wang, Weiyun
    Li, Yuezhen
    Sun, Guoqiang
    Song, Jieping
    Huang, Hui
    Cheng, Chen
    Zhang, Jianguang
    Cheng, Longxian
    Liu, Juntao
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [29] Concordance between whole-exome sequencing and clinical Sanger sequencing: implications for patient care
    Hamilton, Alison
    Tetreault, Martine
    Dyment, David A.
    Zou, Ruobing
    Kernohan, Kristin
    Geraghty, Michael T.
    Hartley, Taila
    Boycott, Kym M.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2016, 4 (05): : 504 - 512
  • [30] Whole-exome sequencing reveals a likely pathogenic LMNA variant causing hypertrophic cardiomyopathy
    Mahdavi, Mohammad
    Mohsen-Pour, Neda
    Maleki, Majid
    Ghasemi, Serwa
    Tabib, Avisa
    Houshmand, Golnaz
    Naderi, Niloofar
    Masoumi, Tannaz
    Pouraliakbar, Hamidreza
    Kalayinia, Samira
    LABORATORY MEDICINE, 2024, 55 (01) : 62 - 70